Issue #27 · November 15, 2026 · ArbLens Weekly

Western Union Terminated the Intermex Deal. Intermex Disagrees.

Western Union terminated its Intermex deal after California delivered conditions it called unacceptable, and Intermex rejected the termination. HealthSpan raised its Surgery Partners offer after a $28 rival proposal, DoubleU Games signed a $16.25 tender offer for DoubleDown, Montana cleared NorthWestern, and the FTC reportedly will hold a last-rites meeting on UniFirst. One new deal joined the tracker, and a catalyst calendar below runs through Nov 20.

72
Active Deals
1.22%
Median Spread
~$665B
Total Value
This Week’s Top Moves
$IMXI Disputed
Western Union walked away. Intermex says it can’t.
On the evening of Nov 10, the contractual outside date, California’s DFPI delivered final Conditions of Approval that Western Union called unacceptable: they would have required material changes to its business model, agent relationships and long-term strategy, which it was not required to accept under the merger agreement. Western Union delivered a termination notice that night, effective 12:00am ET on Nov 12, and withdrew its DFPI application. Neither side owes a termination fee, and each bears its own expenses. Intermex rejected the termination on Nov 11, demanded that Western Union take all actions necessary to close, and said it intends to pursue legal remedies; it describes the DFPI action as a conditional approval, which differs from Western Union’s account. The path here: the DFPI approved in February, extended on Apr 17 and Jul 31, then suspended the second extension 13 days later; New York approved on Aug 13 and the HSR period expired Nov 2. Intermex closed at $6.50 on Nov 10 and $6.29 on Friday, against a $16.00 offer and $9.52 on Nov 2. We now list the deal as terminated. What is left is a stand-alone company, whose Q2 revenue fell 18.6%, with a possible legal claim attached whose outcome is uncertain.
Full analysis on ArbLens →
$SGRY -7.2%
A $28 rival bid forced a raise, and the stock is above the offer
On Nov 9, HealthSpan Partners raised its offer for Surgery Partners to $25.00 in cash from $23.50 (up to about $6B of enterprise value) after an unsolicited, non-binding $28.00 proposal from an unnamed third party (received Nov 3, updated Nov 8). The special committee unanimously found the $28 bid not superior, citing a materially longer or less certain path to closing, greater regulatory risk and fewer contractual protections. The amendment adds a ticking fee: from Mar 1, 2027, holders other than Bain affiliates receive 10% a year on the $25, paid monthly, worth up to about $1.61 per share through the reported Oct 23, 2027 outside date, for a maximum of about $26.61. Bain, at about 39%, is rolling its shares, and the termination fee is about $149.1M. SGRY jumped 14% on Nov 9 and closed Friday at $26.95, about 8% above the cash price, so the stock is pricing the ticking fee and a chance of a higher bid. Closing is still expected in the first quarter of 2027. A negative spread here is optionality, not a return: if the $28 suitor firms up there is upside, and if it walks the price anchors near $25 plus the fee.
Full analysis on ArbLens →
$DDI 3.0%
The proposal became a deal: $16.25 cash, up 44%
In June, we wrote about DoubleDown trading above its $11.25 buyout while the minority held the leverage. On Nov 9, DoubleU Games signed a definitive all-cash tender offer at $16.25 per ADS ($325 per common share), 44% above the original proposal and about 77% above the stock’s April 27 close. A special committee negotiated the terms, with a Kroll fairness opinion. The tender needs a majority of the minority shares (the buyer can reduce, but not waive, that condition with DDI’s consent), is followed by a second-step merger at the same price under the Korean Commercial Act, and is financed by a KRW 300B bridge loan. The outside date is Mar 10, 2027, and the tender has not launched yet. Our June scenarios put a higher bid at $17-20, so $16.25 lands just under that range. DDI closed Friday at $15.77, a 3.0% spread.
Full analysis on ArbLens →
$UNF 40.0%
The FTC’s last-rites meeting is coming
On Nov 13, Seeking Alpha reported that the FTC will soon hold a “last rites” meeting with Cintas and UniFirst, typically the step before a decision on whether to sue. The dollar spread widened from $89 to about $94, and UNF closed the week at $235.39, a ~40% spread against an implied value near $330. The meeting date has not been reported, the FTC has not voted, and no lawsuit has been filed. The rest is unchanged: shareholders approved in June, both sides certified compliance on Oct 2, nothing can close before Dec 11 unless the FTC first closes its investigation, and Cintas owes UniFirst a $350M fee in specified circumstances (reportedly if the deal is terminated on antitrust grounds; a lawsuit alone does not trigger it). Reporting on Oct 29 said no remedies had been offered. A clearance or settlement means about 40% upside; a lawsuit is largely in the price.
Full analysis on ArbLens →
$NWE 0.1%
Montana said yes, 3-2
The Montana PSC approved the $15.4 billion Black Hills-NorthWestern merger on Nov 10, the last state approval needed, with Commissioners Fielder, Bukacek and Bushman voting yes and Welborn and Pinocci no. The order adds two conditions on NorthWestern’s newly acquired Colstrip share (a plan by June 2027 to evaluate whether part of it could serve Montana customers, and analysis of the Puget shares in the 2026 resource plan) and states that rates will not increase because of the merger; most public commenters opposed the deal. That cleared the cliff we flagged last week, since Montana’s PSC reportedly rejected an infrastructure buyout 5-0 in 2007 in a similar last-approval position. The combined company will be named Bright Horizon Energy (ticker HZN) with NorthWestern CEO Brian Bird as CEO. Black Hills guides to a close by year-end, and the companies have not announced a date. NWE trades within about 0.1% of the 0.98-share exchange value.
Full analysis on ArbLens →
$NSC 19.7%
The STB’s concern about the Vena remarks, and a Nov 18 deadline
The STB said it has serious concerns that Union Pacific CEO Jim Vena’s March remarks to shippers, which reportedly suggested he might raise rates for those who oppose the merger, may have discouraged them from speaking freely in the review. The board ordered UP to release the video (it unanimously denied UP’s appeal, and UP published it on Nov 5, saying a customer’s position on the merger will not affect its rates), and CPKC asked the STB to terminate the proceeding. The dollar spread widened from $60 to $63 on Nov 12-13, to about 19.7%. The calendar is unchanged: protests and comments are due Nov 18, DOJ and USDOT comments on Dec 3, responses on Feb 16, 2027 and final briefs on May 28, 2027. The STB’s statutory decision deadline is Aug 28, 2027, and Union Pacific projects a close in the third or fourth quarter of 2027. Wednesday will show how much opposition was filed.
Full analysis on ArbLens →
Added Since Issue #26

$TRMK — Trustmark → Hancock Whitney. All-stock at a fixed 0.7463 Hancock Whitney shares per share (~$3.2B), an 18.6% premium at signing and about 1.78x tangible book. HWC fell 10.2% on dilution concerns, so the implied value dropped from $54.02 to about $48.72 while Trustmark rose about 5%, leaving a ~1.75% spread that moves $0.75 for every $1 in HWC. Closing is expected late in Q1 2027.

Also Since Issue #26

$GSAT — the FCC approved Amazon’s license transfer on Oct 27 (order DA 26-1160), denying the only petition against it and conditioning approval on continued compliance with 1999 and 2004 security agreements. Closing is expected in 2027, and the spread is about 4.3%.

$CSR — both votes passed on Nov 10 (88.1% of IRT votes cast; 99.6% of Centerspace votes cast) despite the activist campaign. IRT can defer closing while it seeks mortgage-lender consents, as late as 10 business days before June 30, 2027.

$ZIM — Hapag-Lloyd’s CEO said on Nov 12 that the improved proposal will be filed very soon but conceded the deal will take longer than the end-2026 target. A formal filing is still unconfirmed, and Q3 results are due Nov 18.

$IRDM — Rocket Lab said on its Nov 9 call that the deal is fully financed and that it is pursuing a timely close; the mid-2027 guidance stands.

Timing resets — $PEN: Boston Scientific now expects an early-first-quarter 2027 close, from the second half of 2026. $TYFG: HBT expects early Q1 2027 after Tri-County holders approved on Oct 29. $MGLD: the company guides to the first half of 2027 or earlier.

Closing Soon

$UTZ — stockholders approved on Nov 13 at $14.25 cash, all regulatory conditions are satisfied, and Utz expects to close on or around Nov 20.

$PCRX — the $36.50 tender offer expires at 11:59pm ET on Monday.

$SSTI — the $8.00 tender plus a CVR of up to $3.00 expires at 11:59pm ET on Tuesday; the stock trades above $8 because the market values the CVR.

$HZO — holders approved on Nov 11 and all regulatory approvals are in; the earliest possible close is Dec 7.

Catalyst Calendar: Nov 16 – 20
Mon Nov 16 — $PCRX: $36.50 cash tender expires (11:59pm ET). $PERI: Q3 results (no call, deal pending).

Tue Nov 17 — $SSTI: tender expires 11:59pm ET ($8.00 plus a CVR of up to $3.00). $D: Virginia SCC evidentiary hearing begins (decision expected Jan 2027).

Wed Nov 18 — $LCII: shareholder votes on the Patrick merger (LCI’s board rejected Monomoy’s $101 proposal). $NSC: STB protests and comments due. $ZIM: Q3 earnings. $VREX: UK national security review period ends.

Thu Nov 19 — $EFSI: shareholder votes, both companies, 1:00pm ET; close expected early Q1 2027. $VREX: HSR waiting period ends.

Fri Nov 20 — $UTZ: closing expected on or around this date.

Just beyond: Nov 24, $MG vote and $VAL votes; Nov 26, $VAL sanction hearing; Nov 28, $ADT go-shop ends; Dec 1, $VAL close expected; Dec 2, $CHMI and MITT votes; Dec 3, $NSC DOJ and USDOT comments; Dec 6, $BHF outside date (extension talks, none signed); Dec 7, $HZO earliest close; Dec 11, $UNF earliest possible close and $PERI go-shop ends.
Top 6 by Spread — November 15, 2026
TickerDealSpreadKey Risk
$BHFAquarian / Brighthouse59.5%Company says approvals won't arrive by the Dec 6 outside date; extension talks, none signed
$UNFCintas / UniFirst40.0%FTC last-rites meeting reported; no suit filed; nothing closes before Dec 11
$ZIMHapag-Lloyd / ZIM19.8%Revised application not confirmed filed; CEO says the deal will take longer
$NSCUnion Pacific / Norfolk Southern19.7%STB protests due Nov 18; decision not before late 2027
$LITEMarvell / Lumentum18.2%Fixed-ratio stock deal; value swings with MRVL; H1 2028 close
$IRDMRocket Lab / Iridium10.1%Collar floor breached, so value moves with RKLB; FCC pending; mid-2027
Top 6 by Risk-Adjusted Expected Return
#TickerWhyGross SpreadAnnualized
#1$GSATMajority consent, HSR, Australia and the FCC all cleared; what remains is international clearances, slow rather than binary.4.3%~7%
#2$IRDMVote done, financing in place, HSR expired; FCC pending. Collar floor breached, so value moves with RKLB.10.1%~16%
#3$CZRVote done; a long but defined path through the FTC Second Request and state gaming approvals.5.8%~16%
#4$SMTIVote done; FTC Second Request with an end date of July 2027, extendable. A small stock leg.5.9%~10%
#5$UNFThe FTC reportedly intends to sue and a last-rites meeting is coming; the market prices a high chance of a block.40.0%~195%
#6$BHFApprovals won't arrive by Dec 6; extension talks hand Aquarian leverage on price. Size for binary risk.59.5%~160%

Annualized figures use ArbLens's modeled expected close, not a deal's outside date or next catalyst, and aren't probability-weighted. The order is unchanged from Issue #26. $GSAT’s FCC approval leaves it with the lowest return in the six but also the lowest risk. $IMXI has been terminated by Western Union (disputed by Intermex) and is no longer a live deal. $SGRY is a bidding situation and $DDI’s spread is thin, so neither qualifies. $ZIM and $NSC remain excluded, and $LITE is excluded for its H1 2028 timeline and acquirer-stock volatility.

From the Blog
Weekly · Issue #26 · November 8
Brighthouse Says It Will Miss Its Deadline. Intermex Has Until Tuesday.
Brighthouse's Dec 6 deadline, Intermex's Nov 10 date, Marvell-Lumentum, and a two-week catalyst calendar.
Weekly · Issue #25 · November 1
The FTC Reportedly Plans to Sue Over UniFirst. Nine New Deals Joined the Tracker.
The reported FTC suit, LCI's rejection of Monomoy, MISTRAS's go-shop, and nine new deals.

Live spreads, spread history charts, What’s Changed logs, and full deal analysis on all 72 active deals.

View All 72 Deals on ArbLens →
A small favor

If you find ArbLens useful, consider sharing it with at least one person who might benefit — a fellow investor, analyst, or anyone who follows M&A. It’s free, and word of mouth is how this community grows. arblens.com

Real-time deal alerts, spread movements, and analysis as they happen — follow @ArbLens between issues.

📬

Get weekly merger arb insights delivered to your inbox — spreads, regulatory updates, and what to watch next.

For informational purposes only. Nothing here constitutes investment advice. Merger arbitrage involves significant risk including deal failure and loss of capital. Data sourced from public filings and third-party sources. Spreads shown are as of November 13-15, 2026 and update nightly on arblens.com.